HER2-TARGETED THERAPIES

In a study of 150 patients with HER2-positive breast cancer treated with trastuzumab, investigators found that heart rate deceleration capacity (DC) was as stronger predictor of trastuzumab-associated cardiotoxicity, compared with baseline left ventricular ejection fraction or heart rate variability, and that lower DC was associated with an earlier onset of cardiotoxicity.